Compare ASMB & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | GLRE |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 481.5M |
| IPO Year | 2010 | 2007 |
| Metric | ASMB | GLRE |
|---|---|---|
| Price | $28.24 | $14.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | ★ 92.6K | 81.3K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 75.00 |
| EPS | N/A | ★ 2.17 |
| Revenue | N/A | ★ $729,777,000.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.86 |
| Revenue Growth | N/A | ★ 4.85 |
| 52 Week Low | $7.76 | $11.57 |
| 52 Week High | $39.71 | $15.12 |
| Indicator | ASMB | GLRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 66.04 |
| Support Level | $26.50 | $12.49 |
| Resistance Level | $30.66 | $15.06 |
| Average True Range (ATR) | 1.46 | 0.32 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 36.74 | 88.28 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.